Mallinckrodt to Report Earnings Results for First Quarter 2023

On April 24, 2023 Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, reported that it will present first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023 (Press release, Mallinckrodt, APR 24, 2023, View Source [SID1234630453]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows:

Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616d
Audio Only Webcast Link (live and replay):
View Source
At the Mallinckrodt website: https://ir.mallinckrodt.com/

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!